FINWIRES · TerminalLIVE
FINWIRES

調査速報:クラウン・キャッスル社第1四半期決算:売上高とFFOは予想を上回り、ファイバー事業の売却は第2四半期に完了の見込み

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。CCIは第1四半期の売上高が10億1,000万ドルとなり、前年同期の10億6,000万ドルから4.8%減少したものの、市場予想を1,600万ドル上回りました。サイト賃貸収入は前年同期比5%減の9億6,100万ドルとなり、これは主にDISHとの契約解除による4,900万ドル、Sprintとの契約解除による500万ドルの影響によるものです。経営陣は、通期のサイト賃貸収入見通しを、中間値で前年同期比5%減の38億5,000万ドルで据え置きました。DISHとSprintの契約解除の影響を除くと、経営陣は2024年のオーガニック成長率を3.5%と見込んでいます。しかしながら、第1四半期のオーガニック成長率は前年同期の3.9%から3.1%に鈍化しており、タワーポートフォリオ全体のリース活動の勢いがやや弱まっていることを示しています。 DISHとの契約解除は、CCIの短期的な業績見通しにとって、依然として大きな経営上および財務上の逆風となっているが、同社は通期の収益見通しとガイダンスを維持しながら、この困難な移行期間をうまく乗り切っているようだ。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703